Feature|Articles|September 17, 2024
- Pharmaceutical Executive: September 2024
- Volume 44
- Issue 9
Pharmaceutical Executive: September 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive September 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 1 year ago
A Care Sea Changeabout 1 year ago
Jan van de Winkel: Antibody Ascensionabout 1 year ago
Biotech Performance Pivot May Be in the Offingabout 1 year ago
Delivery and Disruption: Navigating a Changing Care Terrainabout 1 year ago
Outsourcing’s Evolution in the Pharma Industryabout 1 year ago
A Risk-Reward Reset: Getting Serious About Social Mediaabout 1 year ago
Copay Adjustment Chess Match: What Will Payers Do Next?about 1 year ago
Rx Power Struggle: How Pharma can Flip the PBM ScriptNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Relation Therapeutics Forms $1.7 Billion Multi-Program Collaboration with Novartis Advancing Therapeutics for Atopic Diseases
2
Augmentin XR Becomes First Approval Under Commissioner’s National Priority Voucher Pilot Program
3
FDA Approves Waskyra For Treatment of Wiskott-Aldrich Syndrome
4
EU Opportunities: How EMA Support Programs Can Slash Drug Market Entry Costs by 90%
5
